Immunologically augmented skin flap as a novel dendritic cell vaccine against head and neck cancer in a rat model

Cancer Science

Volumn 106, Issue 2, 2015, Pages 143-150

  Inoue, Keita ^a   Saegusa, Noriko ^a   Omiya, Maho ^a   Ashizawa, Tadashi ^a   Miyata, Haruo ^a   Komiyama, Masaru ^a   Iizuka, Akira ^a   Kume, Akiko ^a   Sugino, Takashi ^a   Yamaguchi, Ken ^a   Kiyohara, Yoshio ^a   Nakagawa, Masahiro ^a   Akiyama, Yasuto ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Dendritic cell; Head and neck cancer; Immuno flap; Local recurrence; Rat model

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; TRANSCRIPTION FACTOR FOXP3; CANCER VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HEAD AND NECK CANCER; IN VITRO STUDY; MIXED LYMPHOCYTE REACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SKIN FLAP; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; UPREGULATION; ANIMAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE MODEL; HEAD AND NECK TUMOR; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; SKIN; SPLEEN; TH1 CELL; TUMOR CELL LINE; TUMOR RECURRENCE;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; HEAD AND NECK NEOPLASMS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-2; NEOPLASM RECURRENCE, LOCAL; RATS; SKIN; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 84927680814     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12586     Document Type: Article

References (33)

1. Curado MP, Hashibe M. Recent changes in the epidemiology of head and neck cancer. Curr Opin Oncol 2009; 21: 194-200.
2. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008; 371: 1695-709.
3. Wong CH, Wei FC. Microsurgical free flap in head and neck reconstruction. Head Neck 2010; 32: 1236-45.
4. Herbst RS, Arquette M, Shin DM et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5577-87.
5. Winquist E, Oliver T, Gilbert R. Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: a systematic review with meta-analysis. Head Neck 2007; 29: 38-46.
6. Strojan P, Corry J, Eisbruch A et al. Recurrent and second primary squamous cell carcinoma of the head and neck: when and how to reirradiate. Head Neck 2013; 2015; 37: 134-50. doi:10.1002/hed.23542.
7. Routray S, Mohanty N. Cancer stem cells accountability in progression of head and neck squamous cell carcinoma: the most recent trends!. Mol Biol Int 2014; 2014: 375325.
8. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy-revisited. Nat Rev Drug Discov 2011; 10: 591-600.
9. Murphy BA. To treat or not treat: balancing therapeutic outcomes, toxicity and quality of life in patients with recurrent and/or metastatic head and neck cancer. J Support Oncol 2013; 11: 149-59.
10. Ramos CA, Narala N, Vyas GM et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother 2013; 36: 66-76.
11. Manzo T, Michelini RH, Sturmheit T, Basso V, Bellone M, Mondino A. Tumor-targeting vaccination instructs graft-vs.-tumor immune responses. Oncoimmunology 2013; 2: e25996.
12. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007; 220: 129-50.
13. Crittenden MR, Thanarajasingam U, Vile RG, Gough MJ. Intratumoral immunotherapy: using the tumour against itself. Immunology 2005; 114: 11-22.
14. de Vries IJ, Lesterhuis WJ, Barentsz JO et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005; 23: 1407-13.
15. Yu JS, Liu GL, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicit antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64: 4973-9.
16. Parsa FD, Spira M. Experimental esophageal reconstruction in rats, with a free groin flap. Plast Reconstr Surg 1978; 62: 271-5.
17. Akiyama Y, Maruyama K, Tai S et al. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma. Int J Oncol 2008; 33: 433-41.
18. Akiyama Y, Maruyama K, Nara N et al. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail. Anticancer Res 2004; 24: 571-7.
19. Dellon AL, Mackinnon SE. Segmentally innervated latissimus dorsi muscle. Microsurgical transfer for facial reanimation. J Reconstr Microsurg 1985; 2: 7-12.
20. Kornfehl J, Formanek M, Knerer B, Vajs A, Moser D, Millesi W. Myocutaneous flaps in patients with head and neck cancer retain their immunological capacities in an activated functional state. J Oral Pathol Med 1997; 26: 29-35.
21. Dempsey MP, Hamou C, Michaels J 5th et al. Using genetically modified microvascular free flaps to deliver local cancer immunotherapy with minimal systemic toxicity. Plast Reconstr Surg 2008; 121: 1541-53.
22. van Schalkwyk MC, Papa SE, Jeannon JP, Guerrero Urbano T, Spicer JF, Maher J. Design of a phase I clinical trial to evaluate intr atumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum Gene Ther Clin Dev 2013; 24: 134-42.
23. Erfani N, Khademi B, Haghshenas MR, Mojtahedi Z, Khademi B, Ghaderi A. Intracellular CTLA4 and regulatory T cells in patients with laryngeal squamous cell carcinoma. Immunol Invest 2013; 42: 81-90.
24. Jie HB, Gildener-Leapman N, Li J et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 2013; 109: 2629-35.
25. Badoual C, Hans S, Merillon N et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73: 128-38.
26. Bourdeaux C, Lurquin C, Jacquemart I et al. Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy. Proc Natl Acad Sci USA 2014; 111: 3502-7.
27. Herold-Mende C, Karcher J, Dyckhoff G, Schirrmacher V. Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine. Adv Otolaryngol 2005; 62: 173-83.
28. Turksma AW, Braakhuis BJ, Bloemena E, Meijer CJ, Leemans CR, Hooijberg E. Immunotherapy for head and neck cancer patients: shifting the balance. Immunotherapy 2013; 5: 49-61.
29. Uchida T, Horiguchi S, Tanaka Y et al. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother 2008; 57: 337-45.
30. Yamasaki K, Horiguchi S, Kurosaki M et al. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol 2010; 138: 255-65.
31. Aarntzen EH, Srinivas M, Bonetto F et al. Targeting of 111In-labeled debdritic cell human vaccines improved by reducing number of cells. Clin Cancer Res 2013; 19: 1525-33.
32. Christian NA, Benencia F, Milone MC et al. In vivo dendritic cell tracking using fluorescence lifetime imaging and near-infrared-emissive polymersomes. Mol Imaging Biol 2009; 11: 167-77.
33. Kurosaki M, Horiguchi S, Yamasaki K et al. Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer. Cancer Immunol Immunother 2010; 60: 207-15.